AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

被引：0

作者：

Kumar, R. ^{[1
,2
]}

Kim, S. H. ^{[3
]}

Zhong, D. ^{[4
]}

Lu, S. ^{[5
]}

Cheng, Y. ^{[6
]}

Chen, M. ^{[7
]}

Cho, E. ^{[8
]}

Clay, T. ^{[9
]}

Kang, J. -H. ^{[10
]}

Lee, G. -W. ^{[11
]}

Sun, M. ^{[12
]}

Shim, B. -Y. ^{[13
]}

Spigel, D. R. ^{[14
]}

Yang, T. -Y. ^{[15
]}

Wang, Q. ^{[16
]}

Chang, G. -C. ^{[17
]}

Yu, G. ^{[18
]}

Wang, R. ^{[19
]}

Luo, X. ^{[19
]}

Zheng, H. ^{[20
]}

Gao, R. ^{[19
]}

Kim, H. R. ^{[21
]}

机构：

[1] New Zealand Clin Res, Christchurch, New Zealand

[2] Univ Otago, Dept Pathol, Dunedin, New Zealand

[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med,Div Hematol & Med Oncol, Seongnam, South Korea

[4] Tianjin Med Univ, Dept Oncol, Gen Hosp, Tianjin, Peoples R China

[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[6] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China

[7] Zhejiang Univ Canc Hosp, Dept Bioinformat, Coll Life Sci, State Key Lab Plant Physiol & Biochem, Hangzhou, Peoples R China

[8] Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea

[9] St John God Subaico Hosp, Dept Med Oncol, Subiaco, WA, Australia

[10] Catholic Univ Korea, Seoul St Marys Hosp, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea

[11] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Div Hematol & Oncol,Dept Internal Med, Jinju, South Korea

[12] Shandong First Med Univ, Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China

[13] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Dept Internal Med, Suwon, South Korea

[14] Sarah Cannon Res Inst SCRI, Tennessee Oncol, PLLC, Nashville, TN USA

[15] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan

[16] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[17] Chung Shan Med Univ Hosp, Div Pulm Med, Dept Internal Med, Taichung, Taiwan

[18] Weifang Med Univ, Weifang Peoples Hosp, Oncol Dept, Weifang, Peoples R China

[19] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[20] BeiGene USA Inc, San Mateo, CA USA

[21] Yonsei Univ, Dept Internal Med, Yonsei Canc Ctr, Coll Med,Div Med Oncol, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

TIGIT antibody; PD-1; inhibitor; metastatic NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.01-07

引用

页码：S375 / S376

页数：2

共 50 条

[41] Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer
Dasari, Arvind
Hubbard, Joleen M.
Eng, Cathy
Yeckes-Rodin, Heather
Ukrainskyj, Stacey M.
Yang, Zhao
Schelman, William R.
Kania, Marek K.
Bekaii-Saab, Tanios S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[42] Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut 1 stage IV NSCLC: phase 1b safety results
Nakagawa, K.
Garon, E. B.
Paz-Ares, L.
Ponce, S.
Corral Jaime, J.
Juan Vidal, O.
Nadal, E.
Kiura, K.
He, S.
Treat, J.
Dalal, R.
Lee, P.
Reck, M.
Novello, S.
ANNALS OF ONCOLOGY, 2017, 28
[43] Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
Adkins, Douglas
Mehan, Paul
Ley, Jessica
Siegel, Marilyn J.
Siegel, Barry A.
Dehdashti, Farrokh
Jiang, Xuntian
Salama, Noha N.
Trinkaus, Kathryn
Oppelt, Peter
LANCET ONCOLOGY, 2018, 19 (08): : 1082 - 1093
[44] A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
Choueiri, Toni K.
Posadas, Edwin M.
Sonpavde, Guru
Figlin, Robert A.
Walsh, Meghara K.
Wall, Kevin C.
Seon, Ben K.
Jivani, Manoi A.
Adams, Bonne J.
Theuer, Charles P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] A phase 1b dose-escalation study of TRC105 (anti-Endoglin Antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
Choueiri, T. K.
Michaelson, M. D.
Posadas, E. M.
Sonpavde, G. P.
Mcdermott, D. F.
Sean, B. K.
Jivani, M. A.
Adams, B. J.
Theuer, C. P.
BJU INTERNATIONAL, 2015, 116 : 4 - 5
[46] A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer
Cecchini, Michael
Kortmansky, Jeremy S.
Cui, Can
Wei, Wei
Thumar, Jaykumar Ranchobdhai
Uboha, Nataliya, V
Hafez, Navid
Lacy, Jill
Fischbach, Neal A.
Sabbath, Kert D.
Gomez, Christina M.
Sporn, Jonathan Reed
Stein, Stacey
Hochster, Howard S.
CANCER, 2021, 127 (09) : 1417 - 1424
[47] Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
Haruru Kotani
Norikazu Masuda
Toshinari Yamashita
Yoichi Naito
Tetsuhiko Taira
Kenichi Inoue
Masato Takahashi
Kan Yonemori
Shigeyuki Toyoizumi
Yuko Mori
Takashi Nagasawa
Natsuki Hori
Hiroji Iwata
Breast Cancer, 2022, 29 : 1088 - 1098
[48] Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
Kotani, Haruru
Masuda, Norikazu
Yamashita, Toshinari
Naito, Yoichi
Taira, Tetsuhiko
Inoue, Kenichi
Takahashi, Masato
Yonemori, Kan
Toyoizumi, Shigeyuki
Mori, Yuko
Nagasawa, Takashi
Hori, Natsuki
Iwata, Hiroji
BREAST CANCER, 2022, 29 (06) : 1088 - 1098
[49] Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
Gao, Bo
Zhao, Jun
Huang, Dingzhi
Sun, Meili
Ma, Zhiyong
Chu, Qian
Liu, Yunpeng
Wang, Zhehai
Li, Xin
Li, Hui
Zhang, Juan
Sun, Jingchao
Peng, Yanyan
Wu, Yi-Long
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 124 - 124
[50] A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Wainberg, Zev A.
Messersmith, Wells A.
Peddi, Parvin F.
Kapp, Amy V.
Ashkenazi, Avi
Royer-Joo, Stephanie
Portera, Chia C.
Kozloff, Mark F.
CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 248 - 254

← 1 2 3 4 5 →